Key result
Recent studies support lower blood pressure targets in select groups of patients with chronic kidney disease and avoiding the use of dual renin-angiotensin system blockade.
Why the study?
Hypertension is a frequent and challenging risk factor for progression in CKD patients, with many failing to reach target blood pressure despite multiple treatments.
Answers are grounded in this paper and cite their sources.
This review highlights recent insights into optimal blood pressure assessment and management in patients with chronic kidney disease, emphasizing lower targets and the avoidance of dual RAS blockade.
Chronic kidney disease (CKD) is common, affecting 6-11% of the population in the developed world. Hypertension is an independent risk factor for CKD progression, and is a frequent finding in patients with CKD. Its prevalence increases as CKD progresses, with over 75% of patients with a glomerular filtration rate <30ml/min having a blood pressure (BP) >140/90mmHg. Despite treatment with multiple antihypertensive agents the majority of CKD patients fail to reach target BP. Recent studies have supported lower BP targets in select groups of patients with CKD as well as avoiding use of dual renin-angiotensin system blockade in all of these patients. Here, we shall review the optimal method of BP assessment in CKD as well as recent insights into its optimal management.
No takes yet. Share an insight, caveat, or question.
Neeraj Dhaun (2018) conducted a review in Chronic kidney disease and hypertension. Blood pressure management was evaluated. Recent studies support lower blood pressure targets in select groups of patients with chronic kidney disease and avoiding the use of dual renin-angiotensin system blockade.
Synapse has enriched 10 related papers. Consider them for comparative context: